Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OLINVYK vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oliceridine is a G protein-biased μ-opioid receptor agonist. It preferentially activates the G protein pathway (associated with analgesia) over β-arrestin recruitment (associated with opioid-related adverse effects like respiratory depression and gastrointestinal dysfunction).
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of acute pain severe enough to require an intravenous opioid analgesic and for which alternative treatments are inadequate
Mild to moderate pain,Fever
Initial adult dose: 1.5 mg intravenously (IV) every 3 to 6 hours as needed. May be titrated in increments of 0.75 mg to 1.5 mg every 3 to 6 hours. Maximum single dose: 4.5 mg. Maximum daily dose: 27 mg.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life is approximately 26–29 hours, supporting once-daily dosing in chronic pain
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily metabolized by CYP3A4 and CYP2D6 to inactive metabolites; also undergoes glucuronidation.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily renal (approximately 90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <5%
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 93–95% bound to albumin and alpha-1-acid glycoprotein
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Approximately 3.5–4.5 L/kg, indicating extensive tissue distribution
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: approximately 70% for extended-release formulation; intravenous: 100%
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
For GFR 15 to 29 m L/min: reduce dose by 50% and monitor for respiratory depression. For GFR <15 m L/min: not recommended. For dialysis: not recommended.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: reduce dose by 50%; consider reducing dose frequency. Child-Pugh Class C: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not approved for use in pediatric patients under 18 years of age; safety and efficacy not established.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Initial dose: 1.5 mg IV every 3 to 6 hours; consider dose reduction to 0.75 mg in patients aged 65 years or older due to increased sensitivity and risk of respiratory depression.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; risks from concomitant use with benzodiazepines or CNS depressants; neonatal opioid withdrawal syndrome; and risks associated with use in patients with compromised respiratory function, especially in elderly, cachectic, or debilitated patients.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Life-threatening respiratory depression; addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or CNS depressants; severe hypotension; adrenal insufficiency; seizure; and withdrawal.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; hypersensitivity to oliceridine.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No specific food interactions. Grapefruit juice has no known interaction. Avoid alcohol consumption due to additive CNS depression.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome. First trimester: Limited data, but opioids as a class are not major teratogens. Second/third trimester: Chronic use may lead to fetal dependence and withdrawal postnatally. Use only if benefit outweighs risk, especially near term.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Oliceridine is excreted in human milk; M/P ratio not available. Breastfeeding not recommended due to potential for infant sedation and respiratory depression. If used, monitor infant for drowsiness, feeding difficulties, and respiratory rate.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pregnancy may alter pharmacokinetics of oliceridine (increased clearance, volume of distribution). No specific dose adjustment guidelines exist; titrate to effective dose and monitor closely for both efficacy and adverse effects.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
OLINVYK (oliceridine) is a mu-opioid receptor agonist with reduced beta-arrestin recruitment, potentially offering a therapeutic window with less respiratory depression at equianalgesic doses. Requires ECG monitoring due to QTc prolongation; avoid in patients with history of long QT syndrome or concurrent QT-prolonging drugs. Do not use more than 27 mg in a 24-hour period due to hepatic metabolite accumulation. Administer only in a hospital setting for short-term intravenous use (≤48 hours).
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
OLINVYK is a strong pain medicine that can cause serious side effects like slowed breathing, low blood pressure, and heart rhythm changes.,Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint, or if you have a fast or irregular heartbeat.,Do not stop taking this medicine suddenly, as withdrawal symptoms may occur.,Do not drive or operate heavy machinery while receiving this medication.,This drug may cause constipation; increase fluid intake and request stool softeners if needed.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OLINVYK vs ACEPHEN, answered by our medical review team.
OLINVYK is a Opioid Analgesic that works by Oliceridine is a G protein-biased μ-opioid receptor agonist. It preferentially activates the G protein pathway (associated with analgesia) over β-arrestin recruitment (associated with opioid-related adverse effects like respiratory depression and gastrointestinal dysfunction).. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OLINVYK and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OLINVYK is: Initial adult dose: 1.5 mg intravenously (IV) every 3 to 6 hours as needed. May be titrated in increments of 0.75 mg to 1.5 mg every 3 to 6 hours. Maximum single dose: 4.5 mg. Maximum daily dose: 27 mg.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OLINVYK and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OLINVYK is classified as Category C. Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome. First trimester: Limited data, but opioids as a class are not major teratogens. Second/. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.